Open Access
Issue
Wuhan Univ. J. Nat. Sci.
Volume 28, Number 4, August 2023
Page(s) 333 - 340
DOI https://doi.org/10.1051/wujns/2023284333
Published online 06 September 2023
  1. Robinson D M, Wellington K. Indapamide sustained release: A review of its use in the treatment of hypertension[J]. Drugs, 2006, 66: 257-271. [CrossRef] [PubMed] [Google Scholar]
  2. Pinto G A, Pastre K I F, Bellorio K B, et al. An improved LC-MS/MS method for quantitation of indapamide in whole blood: Application for a bioequivalence study[J]. Biomedical Chromatography: BMC, 2014, 28(9): 1212-1218. [CrossRef] [Google Scholar]
  3. London G, Schmieder R, Calvo C, et al. Indapamide SR versus candesartan and amlodipine in hypertension: The X-CELLENT study[J]. American Journal of Hypertension, 2006, 19(1): 113-121. [CrossRef] [PubMed] [Google Scholar]
  4. Zhang M Y, Zhang J D, Gao Q, et al. Evaluation procedure for quality consistency of generic nifedipine extended-release tablets based on the impurity profile[J]. American Journal of Analytical Chemistry, 2015, 6(9): 776-785. [CrossRef] [Google Scholar]
  5. Szekely G, Amores de Sousa M C, Gil M, et al. Genotoxic impurities in pharmaceutical manufacturing: Sources, regulations, and mitigation[J]. Chemical Reviews, 2015, 115(16): 8182-8229. [CrossRef] [PubMed] [Google Scholar]
  6. Liu D Q, Kord A S. Analytical challenges in stability testing for genotoxic impurities[J]. TrAC Trends in Analytical Chemistry, 2013, 49: 108-117. [CrossRef] [Google Scholar]
  7. ICH. Stability testing of new drug substances and products (Q1A(R2)) [EB/OL]. [2022-08-06]. https://database.ich.org/sites/default/files/Q1A%28R2%29%20Guideline.pdf. [Google Scholar]
  8. ICH. Stability testing: Photostability testing of new drug substances and products (Q1B). [EB/OL]. [2022-08-06]. https://database.ich.org/sites/default/files/Q1B%20Guideline.pdf. [Google Scholar]
  9. British Pharmacopoeia Commission. British Pharmacopoeia [M]. 2020 Edition. London: The Stationary Office Ltd. Company, 2020. [Google Scholar]
  10. Chinese Pharmacopoeia Commission. Chinese Pharmacopoeia [M]. 2015 Edition. Beijing: China Medicine Science and Technology Press, 2015(Ch). [Google Scholar]
  11. Pharmacopeial Convention U.S.. U.S. Pharmacopoeia and National Formulary (USP43-NF38) [M]. Rockville: United States Pharmacopeial Convention, Inc, 2019. [Google Scholar]
  12. Attia K A M, Nassar M W I, Sharaf El-Din M M K, et al. A stability-indicating QTRAP LC-MS/MS method for identification and structural characterization of degradation products of indapamide[J]. Analytical Methods, 2016, 8(8): 1836-1851. [CrossRef] [Google Scholar]
  13. Gumieniczek A, Galeza J, Berecka A, et al. Chemical stability and interactions in a new antihypertensive mixture containing indapamide and dihydralazine using FT-IR, HPLC and LC-MS methods[J]. RSC Advances, 2018, 8(63): 36076-36089. [NASA ADS] [CrossRef] [PubMed] [Google Scholar]
  14. Palaric C, Molinié R, Cailleu D, et al. A deeper investigation of drug degradation mixtures using a combination of MS and NMR data: Application to indapamide[J]. Molecules, 2019, 24(9): 1764. [CrossRef] [PubMed] [Google Scholar]
  15. Dawud E R, Shakya A K. HPLC-PDA analysis of ACE-inhibitors, hydrochlorothiazide and indapamide utilizing design of experiments[J]. Arabian Journal of Chemistry, 2019, 12(5): 718-728. [CrossRef] [Google Scholar]
  16. Barot T G, Prajapati V, Patel D P K, et al. A validated RP-HPLC method for simultaneous estimation of indapamide impurity (methyl nitrosoindoline) API form [J]. Int J PharmTech Res, 2009, 1: 1287-1296. [Google Scholar]
  17. Tao Y, Wang S, Wang L, et al. Simultaneous determination of indapamide, perindopril and perindoprilat in human plasma or whole blood by UPLC-MS/MS and its pharmacokinetic application[J]. Journal of Pharmaceutical Analysis, 2018, 8(5): 333-340. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.